

## **Information Disclosure Statement**

### **Materiality to Patent – 35 USC 102**

- 1) **Origin of Invention: Conception & Reduction to Practice:** The conception of this invention and the actual reduction to practice occurred simultaneously, due to necessity. The invention was developed in 1999 to treat a medical skin condition called pompholyx, that was non-responsive to available prescriptive medicines or current dermatological treatment. The patient (one of the inventors) had lost the functional use of hands, due to a large proportion of the skin being occupied by open wounds, and skin loss. Prescriptive medicines and over the counter medicines were completely ineffective. The medical advice given to the inventor, was to learn to live with the disease as many do. Based on the observation of the symptoms of this disease, a formulation was developed. The results were surprisingly effective, and worked to establish complete remission in a very short period of time, for this otherwise serious skin condition. Since many individuals live with this disease, and there are few alternatives, the results warrant further experimental investigation. Because pompholyx is a known to be recurring chronic condition, which in rare cases goes into “spontaneous remission”, it was critical that the inventors establish some proof of utility being independent of this phenomenon. In the follow-up investigation, it was confirmed that the remission established was stable or semi-permanent. This disease is known to have flare-ups that are associated with stress, and in time should re-emerge. Fortunately, but unfortunately, over the next couple of years, several flare ups occurred (small blister formations), and each time, the formulation was completely effective in halting disease progression. With this, we were able to capture the effects of the treatment using high-resolution microscopy and present clear evidence of the efficacy. During this period, in 2001, the formula was also tested experimentally against various strains of pathogens in a laboratory, and results indicate the formula is also a potent anti-bacteria, anti-fungal and anti-parasitic agent.
- 2) **Due Diligence:** Two obstacles caused a time delay in the progress of filing a patent. The first being that this is a chronic disease, and establishing utility had to be corroborated and documented during a flare-up period. The second major time delay was in the writing and preparation of the patent application. Both inventors have full time research positions and, since the patent applications would be filed by the inventors (applicants), it was imperative that they had some understanding of what is involved in filing a patent. A large amount of time was required to read through the legal aspects of filing a patent, from the information on the USPTO website, and in the preparation of the document. In particular, this is a very large field to cover in terms of prior art, because of the wealth of information on herbal constituents and their applications.
- 3) **Are there disputes as to inventorship?** No
- 4) **Previous Conventions, Visits, Presentations, Publications, Published Patent Applications by Inventor (s):** None,

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	
Filing Date	03-16-04
First Named Inventor	Mazzio, Elizabeth
Art Unit	
Examiner Name	
Attorney Docket Number	

Sheet 1 of 2

**U. S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
		US- 5,057,501	10-15-1991	Thornfeldt	Worwood Constituent
		US- 5,137,717	08-11-1992	Wixforth	Jugans "
		US- 2003,113,388	06-19-2003	Phan	Turmeric "
		US- 6,248,343	06-19-2001	Jampani et al	Turmeric "
		US- 6,379,673	04-03-2002	Diwan et al	Turmeric / Garlic "
		US- 6,403,654	06-11-2002	De Oliveira	Chamomile "
		US- 5,350,774	09-27-1994	Palou	Chamomile "
		US- 6,248,763	06-19-2001	Scivoletto	Niacin "
		US- 2003,032,617	02-13-2003	Bloch et al	Niacin "
		US- 6,528,071	03-04-2003	Vatter et al	Niacin"
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
		RU - 2124363	01-10-1999	Tereshenko et a	Wormwood "	
		CN - 1360899	07-31-2002	Lan	Wormwood "	
		JP - 063942	03-05-2003	Shizuka	Wormwood "	
		RU - 2118152	08-27-1998	Detsino et al	Wormwood"	
		DE - 10131641	06-27-2002	Koch et al	St Johns Wort"	
		JP - 157176	06-17-1997	Nishibe	St Johns Wort "	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

(Use as many sheets as necessary)

Sheet	2	of	2
-------	---	----	---

Application Number	
Filing Date	03-16-2004
First Named Inventor	Mazzio, Elizabeth
Art Unit	
Examiner Name	
Attorney Docket Number	

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY			
		JP - 002559	01-09-2001	Santa.Mosegena	Turmeric "	
		JP - 143086	06-03-1997	Hidaka	Turmeric "	
		WO - 02/089826	11-24-2002	Bathma et al	Garlic "	
		JP - 175878	06-30-1998	Vazaburo et al	Garlic "	

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, Washington, DC 20231.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.